Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Samir Undevia
Results of a Prospective Phase 2 Study of Pazopanib in Patients With Surgically Unresectable or Metastatic Chondrosarcoma
Cancer
Cancer Research
Oncology
A Pharmacogenetic Study of Aldehyde Oxidase I in Patients Treated With XK469
Pharmacogenetics and Genomics
Molecular Medicine
Genetics
Molecular Biology
Related publications
Results of a Prospective Phase 2 Study of Pazopanib in Patients With Advanced Intermediate-Grade or High-Grade Liposarcoma
Cancer
Cancer Research
Oncology
5O_PRA Phase 1b/2 Study of Omaveloxolone in Combination With Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma
Annals of Oncology
Medicine
Oncology
Hematology
A Prospective Phase II Study of Combined Androgen Blockade in Patients With Androgen Receptor-Positive Metastatic or Locally Advanced Unresectable Salivary Gland Carcinoma
Annals of Oncology
Medicine
Oncology
Hematology
SWOG 0514: A Phase II Study of Sorafenib in Patients With Unresectable or Metastatic Gallbladder Carcinoma and Cholangiocarcinoma
Investigational New Drugs
Oncology
Pharmacology
A Phase II Trial of Gemcitabine and Capecitabine in Patients With Unresectable or Metastatic Gallbladder Cancer or Cholangiocarcinoma: Southwest Oncology Group Study S0202
Cancer Chemotherapy and Pharmacology
Cancer Research
Toxicology
Oncology
Pharmacology
Therapeutic Efficacy and Dosage of Pazopanib for Metastatic or Unresectable Advanced Soft Tissue Sarcomas
Chemotherapy: Open Access
A Phase II Study of NK012, a Polymeric Micelle Formulation of SN-38, in Unresectable, Metastatic or Recurrent Colorectal Cancer Patients
Cancer Chemotherapy and Pharmacology
Cancer Research
Toxicology
Oncology
Pharmacology
A Phase II Study of Axalimogene Filolisbac for Patients With Previously Treated, Unresectable, Persistent/Recurrent Loco-Regional or Metastatic Anal Cancer
Oncotarget
Oncology
Front-Line Treatment With Gemcitabine, Paclitaxel, and Doxorubicin for Patients With Unresectable or Metastatic Urothelial Cancer and Poor Renal Function: Final Results From a Phase II Study
Urology
Urology
